Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Medicine and Dentistry

• Hepatocellular Carcinoma 100%
• Placebo 100%
• Pembrolizumab 100%
• Lenvatinib 100%
• Overall Survival 26%
• Progression Free Survival 21%
• Hazard Ratio 10%
• Oncology 10%
• Systemic Therapy 10%
• Gastrointestinal Bleeding 10%
• Hepatorenal Syndrome 10%
• Apoplexy 5%
• Adverse Event 5%
• Survival Analysis 5%
• Intention-to-Treat Analysis 5%
• Diarrhea 5%
• Liver Disease 5%
• Event Free Survival 5%
• Hepatic Portal Vein 5%
• Aspartate Aminotransferase 5%
• Child-Pugh Score 5%
• American Indian 5%
• Fetoprotein 5%
• Hepatic Encephalopathy 5%